Literature DB >> 20047953

Targets of Raf in tumorigenesis.

Théodora S Niault1, Manuela Baccarini.   

Abstract

Some 25 years ago, Raf was discovered as the transforming principle shared by a murine sarcoma and an avian carcinoma virus. Thus, Raf and tumorigenesis have been connected from the very beginning. Ten years later, the work of many groups instated Raf as the link between Ras, the oncogene most frequently mutated in human cancers, and the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK/ERK) module, which with its manifold substrates can contribute to different aspects of carcinogenesis. Finally, the discovery of activating B-Raf mutations in a subset of human cancers, notably melanomas, conclusively established Raf as a major player in tumor development. Recent studies in animal models now show that endogenous C-Raf is essential for the development and maintenance of Ras-induced epidermal tumors. Surprisingly, the role of C-Raf in this case is not that of an mitogen-activated protein kinase activator, but rather that of an endogenous inhibitor of Rho signaling, expanding the range of tumor-related Raf targets. This review focuses on old and new targets of Raf in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047953     DOI: 10.1093/carcin/bgp337

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  47 in total

1.  c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway.

Authors:  Jens Rauch; Kim Moran-Jones; Valerie Albrecht; Thomas Schwarzl; Keith Hunter; Olivier Gires; Walter Kolch
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

2.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

3.  In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.

Authors:  Zi-jie Wang; Zhi-ning Wan; Xu-dong Chen; Chuan-fang Wu; Guo-long Gao; Rong Liu; Zheng Shi; Jin-ku Bao
Journal:  J Mol Model       Date:  2015-04-02       Impact factor: 1.810

Review 4.  Rho-kinase: regulation, (dys)function, and inhibition.

Authors:  Ehsan Amin; Badri Nath Dubey; Si-Cai Zhang; Lothar Gremer; Radovan Dvorsky; Jens M Moll; Mohamed S Taha; Luitgard Nagel-Steger; Roland P Piekorz; Avril V Somlyo; Mohammad R Ahmadian
Journal:  Biol Chem       Date:  2013-11       Impact factor: 3.915

5.  Clinical significance of nerve growth factor and tropomyosin-receptor-kinase signaling pathway in intrahepatic cholangiocarcinoma.

Authors:  Xiao-Qing Yang; Yun-Fei Xu; Sen Guo; Yi Liu; Shang-Lei Ning; Xiao-Fei Lu; Hui Yang; Yu-Xin Chen
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

6.  Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.

Authors:  Jiancheng Hu; Haiyang Yu; Alexandr P Kornev; Jianping Zhao; Erin L Filbert; Susan S Taylor; Andrey S Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-25       Impact factor: 11.205

7.  Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.

Authors:  Alessia Bottos; Miriam Martini; Federica Di Nicolantonio; Valentina Comunanza; Federica Maione; Alberto Minassi; Giovanni Appendino; Federico Bussolino; Alberto Bardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

8.  Changed genome heterochromatinization upon prolonged activation of the Raf/ERK signaling pathway.

Authors:  Catherine Martin; Songbi Chen; Daniela Heilos; Guido Sauer; Jessica Hunt; Alexander George Shaw; Paul Francis George Sims; Dean Andrew Jackson; Josip Lovrić
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

9.  The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis.

Authors:  Sébastien Bergeron; Etienne Lemieux; Véronique Durand; Sébastien Cagnol; Julie C Carrier; Jacques G Lussier; Marie-Josée Boucher; Nathalie Rivard
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

Review 10.  Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Authors:  Alessia Bottos; Alberto Bardelli
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.